- Home
- CNOBP vs CMMB Comparison
CNOBP vs CMMB Comparison
Compare CNOBP & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOBP
- CMMB
- Stock Information
- Founded
- CNOBP N/A
- CMMB 2004
- Country
- CNOBP United States
- CMMB Israel
- Employees
- CNOBP 493
- CMMB N/A
- Industry
- CNOBP Major Banks
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- CNOBP Finance
- CMMB Health Care
- Exchange
- CNOBP Nasdaq
- CMMB Nasdaq
- Market Cap
- CNOBP N/A
- CMMB 23.0M
- IPO Year
- CNOBP N/A
- CMMB N/A
- Fundamental
- Price
- CNOBP $22.94
- CMMB $1.15
- Analyst Decision
- CNOBP
- CMMB Strong Buy
- Analyst Count
- CNOBP 0
- CMMB 2
- Target Price
- CNOBP N/A
- CMMB $8.50
- AVG Volume (30 Days)
- CNOBP N/A
- CMMB 216.1K
- Earning Date
- CNOBP N/A
- CMMB 08-20-2025
- Dividend Yield
- CNOBP N/A
- CMMB N/A
- EPS Growth
- CNOBP N/A
- CMMB N/A
- EPS
- CNOBP N/A
- CMMB N/A
- Revenue
- CNOBP N/A
- CMMB N/A
- Revenue This Year
- CNOBP N/A
- CMMB N/A
- Revenue Next Year
- CNOBP N/A
- CMMB N/A
- P/E Ratio
- CNOBP N/A
- CMMB N/A
- Revenue Growth
- CNOBP N/A
- CMMB N/A
- 52 Week Low
- CNOBP N/A
- CMMB $0.87
- 52 Week High
- CNOBP N/A
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- CNOBP 57.29
- CMMB 35.03
- Support Level
- CNOBP $22.61
- CMMB $1.17
- Resistance Level
- CNOBP $23.08
- CMMB $1.22
- Average True Range (ATR)
- CNOBP 0.10
- CMMB 0.06
- MACD
- CNOBP -0.01
- CMMB -0.01
- Stochastic Oscillator
- CNOBP 70.55
- CMMB 31.25
About CNOBP ConnectOne Bancorp Inc. Depositary Shares each representing a 1/40th interest in a share of 5.25% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock Series A
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.